Background
Methods
Patient cohorts
Immunohistochemistry
Scanning and annotation
Cell culture
siRNA mediated gene knockdown
Statistical analysis of transcriptomics data
Cell cycle analysis
Immunofluorescence
Senescence assay
Western blot
Statistical analysis
Results
Nuclear fraction of ANLN expression is significantly associated with clinicopathological parameters
Cohort I | Cohort II | |||||
---|---|---|---|---|---|---|
Characteristic | Low ANLN NF n (%) | High ANLN NF n (%) |
p-value | Low ANLN NF n (%) | High ANLN NF n (%) |
p-value |
Age (years) | ||||||
≤ median | 42 (67.7) | 20 (32.3) | 138 (68.0) | 65 (32.0) | ||
> median | 32 (50.0) | 32 (50.0) |
0.043
| 110 (71.0) | 45 (29.0) | 0.544 |
Tumor size (mm) | ||||||
≤ 20 | 42 (72.4) | 16 (27.6) | 99 (76.7) | 30 (23.3) | ||
> 20 | 32 (47.1) | 36 (52.9) |
0.004
| 149 (65.1) | 80 (34.9) |
0.021
|
ER status | ||||||
Negative | 6 (31.6) | 13 (68.4) | 50 (43.9) | 64 (56.1) | ||
Positive | 68 (63.6) | 39 (36.4) |
0.009
| 191 (81.6) | 43 (18.4) |
<0.001
|
PR status | ||||||
Negative | 15 (39.5) | 23 (60.5) | 46 (40.7) | 67 (59.3) | ||
Positive | 59 (67.0) | 29 (33.0) |
0.004
| 188 (82.5) | 40 (17.5) |
<0.001
|
Grade (NHG) | ||||||
I | 16 (100.0) | 0 (0.0) | 36 (97.3) | 1 (2.7) | ||
II | 43 (74.1) | 15 (25.9) | 130 (86.7) | 20 (13.3) | ||
III | 15 (28.8) | 37 (71.2) |
<0.001
| 76 (47.2) | 85 (52.8) |
<0.001
|
Nodal status | ||||||
Negative | 41 (63.1) | 24 (36.9) | 64 (66.0) | 33 (34.0) | ||
Positive | 25 (49.0) | 26 (51.0) | 0.129 | 183 (70.4) | 77 (29.6) | 0.423 |
Ki-67 | ||||||
≤ 10% | 50 (96.2) | 2 (3.8) | 101 (91.8) | 9 (8.2) | ||
> 10% | 22 (30.6) | 50 (69.4) |
<0.001
| 142 (59.4) | 97 (40.6) |
<0.001
|
HER2 status | ||||||
0–2+ | 72 (61.5) | 45 (38.5) | 193 (70.4) | 81 (29.6) | ||
3+ | 2 (22.2) | 7 (77.8) |
0.021
| 28 (58.3) | 20 (41.7) | 0.095 |
High ANLN nuclear fraction is associated with poor patient survival
Univariable analysis | Multivariable analysis | |||
---|---|---|---|---|
HR (95% CI) |
p-value | HR (95% CI) |
p-value | |
Cohort I | ||||
OS | 2.05 (1.10–3.82) |
0.024
| 1.93 (1.03–3.62) |
0.039
a
|
BCSS | 2.34 (1.00–5.47) | 0.051 | ||
RFS | 1.88 (0.90–3.97) | 0.095 | ||
Cohort II | ||||
OS | 1.91 (1.39–2.63) |
<0.001
| 1.61 (1.09–2.39) |
0.018
b
|
BCSS | 1.93 (1.38–2.69) |
<0.001
| 1.58 (1.05–2.38) |
0.027
b
|
RFS | 1.75 (1.27–2.40) |
0.001
| 1.67 (1.13–2.48) |
0.010
b
|